NovaBay Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 66.22%

NovaBay Pharmaceuticals Inc (NBY) has an Asset Resilience Ratio of 66.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NBY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$2.31 Million

Cash + Short-term Investments

Total Assets

$3.49 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how NovaBay Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NBY current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down NovaBay Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read NBY total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$2.31 Million	66.22%
Short-term Investments	$0.00	0%
Total Liquid Assets	$2.31 Million	66.22%

Asset Resilience Insights

Very High Liquidity: NovaBay Pharmaceuticals Inc maintains exceptional liquid asset reserves at 66.22% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

NovaBay Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare NovaBay Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for NovaBay Pharmaceuticals Inc (2005–2024)

The table below shows the annual Asset Resilience Ratio data for NovaBay Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	12.56%	$430.00K	$3.42 Million	-22.08pp
2023-12-31	34.65%	$3.13 Million	$9.03 Million	+1.95pp
2022-12-31	32.70%	$5.36 Million	$16.40 Million	+1.40pp
2021-12-31	31.30%	$7.50 Million	$23.98 Million	-47.14pp
2020-12-31	78.44%	$11.95 Million	$15.24 Million	+16.61pp
2019-12-31	61.83%	$6.94 Million	$11.22 Million	+27.82pp
2018-12-31	34.00%	$3.18 Million	$9.36 Million	+2.26pp
2017-12-31	31.74%	$3.20 Million	$10.08 Million	-30.10pp
2016-12-31	61.84%	$9.51 Million	$15.38 Million	--
2015-12-31	0.00%	$0.00	$5.08 Million	--
2014-12-31	0.00%	$0.00	$7.54 Million	--
2013-12-31	16.31%	$2.55 Million	$15.65 Million	-5.18pp
2012-12-31	21.50%	$4.13 Million	$19.23 Million	-14.27pp
2011-12-31	35.77%	$5.71 Million	$15.96 Million	+27.57pp
2010-12-31	8.20%	$1.27 Million	$15.52 Million	+6.49pp
2009-12-31	1.71%	$300.00K	$17.52 Million	-45.99pp
2007-12-31	47.71%	$11.41 Million	$23.92 Million	-4.40pp
2006-12-31	52.11%	$6.18 Million	$11.87 Million	+23.92pp
2005-12-31	28.19%	$1.00 Million	$3.56 Million	--

pp = percentage points

About NovaBay Pharmaceuticals Inc

NYSE MKT:NBY USA Biotechnology

Market Cap

$32.22 Million

Market Cap Rank

#23605 Global

#5127 in USA

Share Price

$1.21

Change (1 day)

+4.31%

52-Week Range

$0.43 - $19.16

All Time High

$10718.75